Stock Photo newspapers
Press Release No. 1
/ January 05, 2005 /
Berlin

Cholesterol and Brain Development

Holoprosencephaly (HPE) is the most common developmental forebrain anomaly in humans and is caused by the failure of the embryonic forebrain (the prosencephalon) to sufficiently divide into the two lobes of the cerebral hemispheres. The result is a single-lobed brain structure and severe skull and facial defects. About 1 in 250 pregnancies miscarries as a result of severe HPE. In less severe cases, about one in 16,000 babies is born with minor brain developmental and facial deformities that may affect the eyes, nose, and upper lip, such as median cleft lip and palate. HPE has several causes including prenatal viral infections or alcohol abuse during pregnancy. In many cases, a genetic defect in the metabolism of cholesterol results in HPE. Thus, some individuals with HPE are unable to produce cholesterol.

Now, scientists of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch in Germany have been able to show that a gene defect in one of the receptors for cholesterol, the receptor megalin, is responsible for severe damages of the forebrain and holopresencephaly in mice. Megalin is primarily produced by the embryonic tissue which later develops into the central nervous system. These results achieved by Robert Spoelgen, Dr. Annette Hammes, and Uwe Anzenberger of the research group of Professor Thomas Willnow have now been published online by the journal Development; http://dev.biologists.org/cgi/content/full/132/2/405; (January 2005, Vol. 132, Issue 2, pp. 405-414).*

*LRP2/megalin is required for patterning of the ventral telencephalon

Robert Spoelgen*, Annette Hammes*, Uwe Anzenberger*, Dietmar Zechner, Olav M. Andersen, Boris Jerchow and Thomas E. Willnow

Max-Delbrueck-Center for Molecular Medicine, Berlin, 13092, Germany

*Authors contributed equally

Author for correspondence (e-mail: willnow@mdc-berlin.de)

Barbara
Bachtler
Press
and Public Affairs
MaxDelbrück
Center for Molecular Medicine (MDC)
Berlin-Buch
Robert-Rössle-Straße
10
13125 Berlin
Germany
Phone.:
+49 (0) 30 94 06 - 38 96
Fax:  +49 (0) 30 94 06 - 38 33
e-mail:
presse@mdc-berlin.de
http://www.mdc-berlin.de/en/news

Related news & events

Fischbowl Discussion

During a fish bowl discussion, visitors were able to discuss the topic of women in science with (from left to right) Jessica Rohmann, Anne-Sophie Waag, Christina Rouvray, Susanne Wolf and Heike Graßmann.
 

© Svea Pietschmann
Press Release No. 8

STEM Passion: A journey inspired by women in science

The artists Elisabetta Citterio and Claudia Cagliano have created portraits of nearly 60 female researchers from nine countries. Twenty-five of them can be viewed in the "STEM Passion" exhibition until March 12, 2024 in the Rahel Hirsch Center for Translational Medicine Berlin.
scientific image

Gram-negative bacterial pathogens (green) surrounded by a protein coat of GBP1 proteins (magenta).

© Miriam Kutsch @CAi, Heinrich-Heine-Universität Düsseldorf
Press Release No. 3

How a protein fights off bacteria

The details of many immune defense mechanisms are still unknown, but a new study sheds light on one such mechanism. Writing in “The EMBO Journal”, researchers led by Oliver Daumke and Misha Kudryashev of the Max Delbrück Center describe exactly how GBP1 proteins render bacteria harmless by encapsulating them.
Gaetano Gargiulo

Gaetano Gargiulo.

© David Ausserhofer, MDC
Press Release No. 2

Third ERC Grant for Gaetano Gargiulo

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.
Scientific image

Red staining of dead cells in DDX1-MYCN co-amplified neuroblastoma after treated with rapamycin. 

© Henssen Lab, Max Delbrück Center 
Press Release No. 1

Passenger genes allow more targeted cancer therapy

A tumor often arises when cancer genes multiply. In this process, additional genes act as hitchhikers, potentially creating previously unknown vulnerabilities that open the door to new therapeutic approaches. This finding is reported by a team led by ECRC-scientists Anton Henssen and Jan Dörr in "Cancer Discovery."